Bleeding while on birth control
Pro Research Analysisby 
Searched over 200M research papers
Bleeding While on Birth Control: Insights from Recent Research
Continuous Combination Oral Contraceptive Pills and Bleeding Reduction
Continuous use of combination oral contraceptive pills (COCPs) has been shown to significantly reduce bleeding days compared to the traditional 28-day cycle. A study comparing traditional 28-day cycles with continuous administration of a low-estrogen dose combination pill found that continuous use led to a substantial decrease in bleeding days. Specifically, 49%, 68%, and 88% of women reported no bleeding during cycles 2, 6, and 12, respectively. Additionally, amenorrhea or infrequent bleeding was present in 68% of continuous users during cycles 1-3, increasing to 88% during cycles 10-12 .
Progesterone Therapy in Early Pregnancy Bleeding
Progesterone therapy has been investigated for its potential to improve pregnancy outcomes in women experiencing bleeding in early pregnancy. A large randomized trial found that progesterone therapy did not significantly increase the incidence of live births compared to placebo. The study included 4153 women and concluded that the incidence of live births after at least 34 weeks of gestation was similar between the progesterone and placebo groups .
Estradiol-Based Oral Contraceptives and Bleeding Patterns
A comparative study of an oral contraceptive containing estradiol valerate/dienogest (E2V/DNG) versus a monophasic oral contraceptive with ethinyl estradiol/levonorgestrel (EE/LNG) revealed that E2V/DNG users experienced fewer bleeding and spotting days. The study reported that the duration and intensity of scheduled withdrawal bleeding were reduced with E2V/DNG compared to EE/LNG. However, the incidence of intracyclic bleeding was similar between the two groups .
Combined Hormonal Contraceptives for Heavy Menstrual Bleeding
Combined hormonal contraceptives (CHCs), including pills, vaginal rings, and patches, have been evaluated for their efficacy in treating heavy menstrual bleeding (HMB). Moderate-quality evidence suggests that COCPs significantly reduce HMB, with a step-down estrogen and step-up progestogen regimen improving response to treatment and lowering menstrual blood loss compared to placebo. However, the levonorgestrel-releasing intrauterine system (LNG IUS) was found to be more effective than COCPs in reducing menstrual blood loss .
Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System
The segesterone acetate/ethinyl estradiol (SA/EE) contraceptive vaginal system (CVS) has shown favorable bleeding profiles. In a pooled analysis of phase 3 trials, users reported good cycle control with low discontinuation rates due to unacceptable bleeding. Unscheduled bleeding/spotting was reported by 13.2% to 21.7% of women per cycle, and scheduled bleeding was documented by 98% of participants .
Estetrol-Containing Combined Oral Contraceptives
A phase II study assessed the bleeding patterns and cycle control of oral contraceptives containing estetrol (E4) combined with either drospirenone (DRSP) or levonorgestrel (LNG). The study found that the 15 mg E4/DRSP combination had the most favorable bleeding pattern and cycle control, with the lowest frequencies of unscheduled bleeding and absence of withdrawal bleeding by cycle 6 .
Conclusion
Recent research highlights the effectiveness of various hormonal contraceptives in managing bleeding patterns. Continuous use of COCPs, estradiol-based oral contraceptives, and the SA/EE CVS have shown promising results in reducing bleeding days and improving cycle control. Additionally, CHCs are effective in treating HMB, with the LNG IUS being particularly effective. These findings provide valuable insights for women and healthcare providers in selecting the most suitable contraceptive method based on bleeding patterns and individual preferences.
Sources and full results
Most relevant research papers on this topic